Vapotherm (NYSE:VAPO) is scheduled to be announcing its earnings results after the market closes on Wednesday, May 5th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter. Vapotherm has set its Q1 2021
After-Hours guidance at EPS and its FY 2021
After-Hours guidance at EPS.Individual that wish to register for the company’s earnings conference call can do so using this link.
Vapotherm (NYSE:VAPO) last released its quarterly earnings data on Wednesday, February 24th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.06. Vapotherm had a negative return on equity of 51.59% and a negative net margin of 47.80%. The company had revenue of $40.91 million for the quarter, compared to the consensus estimate of $40.58 million. On average, analysts expect Vapotherm to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Shares of NYSE:VAPO opened at $22.39 on Tuesday. Vapotherm has a 12-month low of $20.29 and a 12-month high of $54.42. The business’s fifty day simple moving average is $23.41 and its 200-day simple moving average is $27.49. The company has a market capitalization of $577.82 million, a PE ratio of -10.66 and a beta of -1.50. The company has a current ratio of 5.96, a quick ratio of 5.13 and a debt-to-equity ratio of 0.33.
A hedge fund recently bought a new stake in Vapotherm stock. OLD Mission Capital LLC acquired a new position in shares of Vapotherm, Inc. (NYSE:VAPO) in the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 12,300 shares of the company’s stock, valued at approximately $357,000. 70.35% of the stock is owned by institutional investors and hedge funds.
VAPO has been the subject of a number of recent analyst reports. Canaccord Genuity reissued a “buy” rating and issued a $40.00 price objective on shares of Vapotherm in a research report on Thursday, January 14th. Zacks Investment Research lowered Vapotherm from a “hold” rating to a “sell” rating in a research note on Wednesday, April 28th. Finally, Piper Sandler reduced their price objective on Vapotherm from $39.00 to $36.00 and set an “overweight” rating for the company in a research note on Thursday, February 25th.
Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.
See Also: What is the CAC 40 Index?
Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.